Boston An independent LDT provider

Investor relations Welcome to our investor section

Immunovia’s Presentation of Q3 2022 Report, on November 10, 2022

View Report & Presentation
Featured presentation

Our latest presentation

Immunovia, Philipp Mathieu, CEO and President, presented at Jefferies London Healthcare Conference on November 16, 2022

View presentation
Lab oerson decorative image Immunovia

IMMray™ Pancan-d is exclusively provided by Immunovia, Inc.

IMMray™ PanCan-d is provided as a laboratory developed test (LDT) exclusively by Immunovia, Inc. in the US.

Read more

The Share

The Immunovia AB share is, since 3 April 2018, traded on Nasdaq Stockholm. Immunovia has one class of shares. The Company has a registered share capital of SEK 1,131,579.05 allocated among 22,631,581 shares. The par value of the shares is SEK 0.05 per share.

Trading information
Ticker on Nasdaq Stockholm: IMMNOV
ISIN-code: SE0006091997
LEI-code: 549300KHWL6KK1XGUO81
The shares are registered by Euroclear Sweden.

Read more

IR Contact

If you have further questions, please contact our IR contact.

Read more


If you are interested in receiving our press releases and reports, please click on “Subscribe”.

Subscribe here